Back to top

Analyst Blog

The healthcare sector has been witnessing several acquisitions since the beginning of 2014. Stryker Corporation (SYK - Analyst Report) acquired Pivot Medical, Inc. in March while ThermoFisher Scientific, Inc. (TMO - Analyst Report) completed the buyout of Life Technologies Corporation in February. Major drug retailer Safeway Inc. (SWY - Analyst Report) will soon be acquired by AB Acquisitions LLC., privately held and controlled by Cerberus Capital Management, L.P.    

In the same vein, Bio-Rad Laboratories, Inc. (BIO - Snapshot Report) also recently acquired GnuBIO, Inc. Financial details of the transaction remain undisclosed.

GnuBIO is a privately-held life sciences company that has developed a fast and fully integrated droplet-based DNA sequencing platform. The platform combines all the functions of DNA sequencing into a single, integrated workflow for medical diagnostics and research markets and delivers results within hours. Thus, this time-and-cost effective technology has clearly enabled GnuBIO to develop a competitive advantage over other sequencing technologies.

Bio-Rad reports revenues under two major segments -- Life Science and Clinical Diagnostics. Life Science accounted for 33.3% of Bio-Rad’s total revenues in 2013. Growth in this segment was driven by sales from the newly acquired AbD Serotec, droplet digital PCR and cell biology product lines.

It is worth noting in this regard that Bio-Rad had acquired AbD Serotec, a division of MorphoSys AG in Jan 2013, in order to have access to AbD Serotec's comprehensive catalog of antibodies thereby boosting its portfolio.The integration of GnuBio’s innovative DNA sequencing technology with the Life Science segment should strengthen Bio-Rad’s foothold in the area of droplet digital PCR.

In order to expand its offerings under the droplet digital PCR system, Bio-Rad had launched PrimePCR assays in Jul 2013. These innovatively predesigned assays for mutation detection and copy number variation provide single-copy PCR resolution without a standard curve.

The Clinical Diagnostics segment contributed 66.2% of total revenue in 2013. Growth in this segment came on the back of higher revenues from quality controls, diabetes and the BioPlex 2200 system.  The DNA sequencing technology of GnuBIO seems to be appropriate for the clinical diagnostics sequencing market.

Bio-Rad has a history of successfully integrating the business and assets of the acquired firms ( the company acquired five firms since 2011) with its own business segments. However, we would like to remain on the sidelines and wait until more visibility is obtained on how well Bio-Rad capitalizes on the new technology acquired.

Currently, Bio-Rad carries a Zacks Rank #4 (Sell).

Read the Full Research Report on BIO
Read the Full Research Report on SYK
Read the Full Research Report on TMO
Read the Full Research Report on SWY


Zacks Investment Research

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.38 +3.79%
BITAUTO HOL… BITA 80.37 +3.40%
CHINA BIOLO… CBPO 47.65 +2.74%
YY ADS YY 87.63 +2.19%
SPIRIT AERO… SPR 37.78 +2.00%